Detailed results from randomized controlled Bentrio® trial in seasonal allergic rhinitis published in Allergy journal Study met primary efficacy endpoint of improvement in nasal symptoms (p = 0.013) Corroborated by statistically significant improvement in health-related quality of life and reduced need for relief medication Study outcomes support plans for further international expansion HAMILTON, BERMUDA -- April 24, 2024... Read More

Management to host conference call today, April 10, at 8.30 a.m. EDT RNA delivery business progressing with new collaborations, potential new applications Partnering of legacy assets underway as Company transitions to focused RNA delivery technology provider Achieved 85% reduction in net loss to CHF 3.9 million and eliminated financial debt Finished year with shareholders’ equity of CHF 6.5 million, improved by CHF 14.8... Read More

Hamilton, Bermuda, April 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it will host its Full Year 2023 Financial Results and Business Update Call on Friday, April 10, 2024. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will... Read More

Univercells to test proprietary mRNA vaccine delivered with Altamira’s SemaPhore™ nanoparticles Targeting safer and accessible mRNA vaccines HAMILTON, BERMUDA, March 25, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it has entered into a collaboration... Read More

Independent peer-reviewed study shows enhanced cell transduction with adeno-associated virus (AAV) vectors, commonly used in gene therapy, when integrating Altamira’s peptide-based delivery technology Increased potency may help to reduce AAV immunogenicity and resistance to AAVs in certain cell types HAMILTON, BERMUDA, Feb. 7, 2024 -- Altamira Therapeutics Ltd. ( Nasdaq: CYTO) ("Altamira" or the "Company"), a company... Read More

Altamira’s poly KRAS mut siRNA shown to knock down at least 65-91% of KRAS mutations in colorectal, non-small cell lung, and pancreatic cancer cell lines Fresh experimental data expected to strengthen Altamira’s intellectual property around its AM-401 nanoparticles for the treatment of KRAS-driven cancers HAMILTON, BERMUDA, Jan. 24, 2024 -- Altamira Therapeutics Ltd. (Nasdaq: CYTO) ("Altamira" or the "Company"), a company... Read More

Altamira’s two flagship programs, AM-401 and AM-411, designed for KRAS-driven cancer and rheumatoid arthritis, serve to demonstrate the technology’s capability to enhance therapeutic efficacy HAMILTON, BERMUDA Jan. 8, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, announced... Read More

HAMILTON, BERMUDA, Dec. 29, 2023 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA, Dec. 29, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, announced that it received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") on December 28,... Read More

Company hosts Investor and Business Update call on December 11 at 8:30 a.m. ET Partial spin-off of Bentrio® business first step in transition to become ‘pure play’ RNA delivery company Transition expected to complete in 2024 through partnering of further legacy assets Spending levels and cash burn aligned with strategic repositioning and to decrease significantly in 2024 Free of financial debt following early repayment of... Read More

HAMILTON, BERMUDA , Dec. 05, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced today that it will host an Investor and Business Update Call on Monday, December 11, 2023, 8:30 a.m. ET. The presentation will be available via teleconference or webcast with audio and... Read More

Partial spin-off of Bentrio® completed to increase focus on RNA delivery activities Retains 49% in Altamira Medica AG, and secures 25% of future licensing revenue HAMILTON, BERMUDA, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it recently received a... Read More

Initiates Strategic Repositioning to Focus on Company’s Core RNA Delivery Technology Altamira Therapeutics retains 49% in Altamira Medica AG, and secures 25% of future licensing revenue Hamilton, Bermuda, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it has entered into a... Read More

Hamilton, Bermuda, Nov. 10, 2023 (GLOBE NEWSWIRE) -- November 10, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it has received an “Intention to Grant” notice from the European Patent Office (EPO) for its patent application titled “Intranasal Composition Comprising Betahistine”... Read More

Fresh data from randomized controlled NASAR clinical trial further demonstrate efficacy and tolerability of Bentrio® nasal spray in treatment of seasonal allergic rhinitis Study meets both primary and secondary efficacy endpoints of improvement in reflective and instantaneous Total Nasal Symptom Scores (p = 0.013 and 0.039) Corroborated by statistically significant improvement in health-related quality of life secondary... Read More

Company hosts 1H 2023 Financial Results and Business Update call today at 8 a.m. ET First research collaboration with biopharmaceutical company initiated for OligoPhore™ platform Partnering discussions for legacy assets progressing with conclusion of clinical development program and opening of IND as key milestones for Bentrio® and AM-125 Significant strengthening of shareholders’ equity and balance sheet HAMILTON, BERMUDA,... Read More

HAMILTON, BERMUDA , Sept. 06, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced that it will host its First Half of 2023 Financial Results and Business Update Call on Tuesday, September 12, 2023. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver... Read More

HAMILTON, BERMUDA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its founder, Chairman, and CEO Thomas Meyer will be presenting at the H.C. Wainwright 25 th Annual Global Investment Conference, being held virtually and in person on September 11-13, 2023,... Read More

HAMILTON, BERMUDA, July 20, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced today that it has entered into an exclusive agreement with Pharma Nordic AS for the marketing and distribution of Bentrio®, a nasal spray for protection against airborne allergens, in Norway and... Read More

Detailed results from house dust mite trial published in Clinical and Translational Allergy Study demonstrates statistically significant alleviation of nasal symptoms of allergic rhinitis HAMILTON, BERMUDA, July 17, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced the... Read More

HAMILTON, BERMUDA / ACCESSWIRE / July 6, 2023 / Altamira Therapeutics Ltd. ("Company") (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, announced today the pricing of a public offering of 11,111,112 common shares (or pre-funded warrants in lieu thereof) accompanied by common warrants to purchase up to 11,111,112 common shares, at a combined public... Read More

Heqet will test nanoparticles based on Altamira’s OligoPhore delivery platform in the regeneration of damaged heart tissue HAMILTON, BERMUDA , July 05, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that it has entered into a collaboration and option... Read More

HAMILTON, BERMUDA / ACCESSWIRE / June 15, 2023 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that the U.S. Food and Drug Administration ("FDA") has completed its safety review of the Company's Investigational New Drug (IND) application for AM-125 (betahistine nasal spray) in acute vestibular... Read More

HAMILTON, BERMUDA / ACCESSWIRE / May 31, 2023 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced the publication of a peer-reviewed article in the International Journal of Molecular Sciences (IJMS) reviewing the challenges in the safe and effective delivery of RNA molecules to target cells beyond the liver. The paper titled,... Read More

Bentrio® meets primary efficacy endpoint in NASAR clinical trial in seasonal allergic rhinitis Clinically relevant and statistically significant improvement in Total Nasal Symptom Score over saline nasal spray control (p = 0.012) Bentrio efficacy and tolerability rated as "good" or "very good" by 63.5% and 73.5% of study participants NASAR concludes Altamira's clinical development program for Bentrio in allergic rhinitis... Read More

Management will host an investor conference call today, May 16th, at 8 a.m. Eastern Company is advancing OligoPhore™ / SemaPhore™ platform for extrahepatic RNA delivery and efficient endosomal release; expects first research collaborations with biopharmaceutical companies in 2023 Filed IND submission with FDA for AM-125 in acute vestibular syndrome ‘Showcase' RNA development programs AM-401 and AM-411 progressing in... Read More

HAMILTON, BERMUDA / ACCESSWIRE / May 12, 2023 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing and commercializing RNA delivery technology for extrahepatic targets, announced that it will host its Fiscal Year 2022 Financial Results and Business Update Call on Tuesday, May 16, 2023. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Paneda will deliver prepared remarks followed by a Q&A... Read More

HAMILTON, BERMUDA / ACCESSWIRE / May 1, 2023 / Altamira Therapeutics ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its founder, chairman, and CEO Thomas Meyer will be presenting at the Sidoti Micro-Cap Conference, being held virtually on May 10 - 11, 2023. Event : Sidoti Micro-Cap Virtual Conference Date :... Read More

Detailed results from TRAVERS trial addressing acute vestibular syndrome with AM-125 (intranasal betahistine) published in Otology & Neurotology Study demonstrates proof of concept and shows good tolerability TRAVERS shows time and dose dependent acceleration of vestibular compensation and alleviation of signs and symptoms of vestibular dysfunction Altamira intends to partner or divest AM-125, part of its legacy assets, in a... Read More

Altamira's peptide-based SemaPhore™ nanoparticle technology confers great stability to mRNA, is non-immunogenic and non-toxic, enabling delivery to extrahepatic targets and efficient endosomal release Continued momentum in mRNA vaccines and therapeutics with over 840 programs under development, according to fresh data from Beacon RNA database by Hanson Wade Limitations of hitherto dominant lipid nanoparticle (LNP)... Read More

Published meta-analysis shows statistically significant improvement in dizziness handicap for betahistine treatment over standard of care procedure alone in patients suffering from BPPV Altamira to file IND application for intranasal betahistine (AM-125) with FDA in May 2023, including protocol for Phase 2 clinical trial in BPPV Altamira intends to partner or divest AM-125 as part of its legacy assets in a strategic pivot to... Read More

Preprint of results from animal study shows restriction of tumor growth in mice treated with ZBTB46 mRNA nanoparticles based on Altamira’s SemaPhore™ delivery technology Nanoparticle treatment combined with immune checkpoint inhibitor results in synergistic control of tumor growth HAMILTON, BERMUDA, March 22, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to... Read More

Data to be presented at Osteoarthritis Research Society International World Congress in Denver March 17-20, 2023 Animal study shows effective attenuation of osteoarthritis progression and functional improvement in mice treated with DNMT3B mRNA nanoparticles based on Altamira's SemaPhore™ delivery technology HAMILTON, BERMUDA / ACCESSWIRE / March 15, 2023 / Altamira Therapeutics ("Altamira" or the "Company") (Nasdaq:CYTO), a... Read More

Bentrio ® remained detectable by fluorescence for up to 210 minutes in subjects' nasal passages vs. 60 minutes with saline nasal spray control Long nasal residence time supports extended protective effects against airborne allergens and other potentially harmful particles HAMILTON, BERMUDA / ACCESSWIRE / March 3, 2023 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address... Read More

Altamira’s ability to target different KRAS mutations with a single polyvalent siRNA sequence illustrates versatility and potential of RNA therapeutics compared with conventional small molecule approaches Analysts project global market for KRAS inhibitors to be more than $4B by 2029 HAMILTON, BERMUDA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (Nasdaq:CYTO), a company developing RNA-based therapeutics that... Read More

House dust mite study shows statistically significant reduction in symptoms vs. no protection Grass pollen study shows faster onset of action and superior efficacy ratings by patients Bentrio® shows wider nasal cavity distribution, for 3.5 x more time, vs saline spray HAMILTON, BERMUDA / ACCESSWIRE / February 14, 2023 / Altamira Therapeutics Ltd. (Nasdaq:CYTO), a company dedicated to developing therapeutics that address... Read More

New, trends and future of RNA-based therapeutics Company's OligoPhore TM / SemaPhore TM polyplexes provide for efficient delivery of siRNA payloads into extrahepatic target cells Company's latest research and insights into RNA-based therapies Alternatives to LNPs and how Altamira's proprietary R&D is different from lipid-based solutions HAMILTON, BERMUDA / ACCESSWIRE / February 7, 2023 / Altamira Therapeutics Ltd.... Read More

Process for divestiture / partnering of legacy assets continues Strong data from Bentrio ® NASAR study reinforces its therapeutic benefit for allergic rhinitis Case for Bentrio’s protective effect in viral infection prophylaxis still intact Restructuring of FiveT convertible loan including extension of maturity HAMILTON, BERMUDA, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (Nasdaq:CYTO), a company dedicated... Read More

Interim analysis of Australian NASAR trial in seasonal allergic rhinitis shows statistically significant improvement with Bentrio® in nasal symptom primary endpoint over saline nasal spray comparator NASAR main trial phase completed; full read-out expected in Q2 2023 Top line data from COVAMID trial in acute COVID-19 show trend for more pronounced reduction in nasal viral load and symptoms than no treatment, but primary... Read More

Hamilton, Bermuda, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Company COO Dr. Pañeda will discuss SemaPhore TM platform’s functionality with mRNA, and: Peptide-based platform for extrahepatic delivery The extrahepatic success of, and prospects for, SemaPhore vs other liver-restricted delivery methods Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs,... Read More

Strategic Bentrio TM partnering or divestiture process enters decisive phase Partnering or divestiture process for inner ear therapeutics assets ongoing Implementing new organizational structure to support strategic focus on RNA business Promoted Covadonga Pañeda, Ph.D., from Chief Development Officer to Chief Operating Officer Database about to be locked in acute COVID-19 trial with Bentrio; top-line data expected by early... Read More

Swift progress of study enrollment - midpoint of 50 patients reached Interim analysis confirmed target enrollment of 100 patients Completion of enrollment expected by early January 2023 HAMILTON, BERMUDA / ACCESSWIRE / December 2, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it has reached the midpoint for... Read More

Hamilton, Bermuda, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Initiative is Nuance’s first step in penetrating Chinese market with Bentrio TM Densely populated Hong Kong (7.3 million) remains negatively impacted by COVID-19 Nuance Pharma to file for marketing approval in Macao, Mainland China and South Korea in 2023 Altamira Therapeutics Ltd. (NASDAQ: CYTO), a company dedicated to developing therapeutics that address important unmet... Read More

Animal study shows effective protection of mitochondria from oxidative damage and reduced plaque vulnerability in advanced atherosclerosis following treatment with SOD2 mRNA nanoparticles based on Altamira's SemaPhore™ technology Data presented at American Heart Association Annual Scientific Sessions Chicago 2022, earlier this month HAMILTON, BERMUDA / ACCESSWIRE / November 22, 2022 / Altamira Therapeutics ("Altamira" or the... Read More